VEGFA and cancer: In line with this, anti-angiogenetic treatment targeting VEGF with monoclonal antibodies, e.g., Bevacizumab, has been successfully established in 1st and 2nd line treatments for numerous cancer entities [20,21]; however, this has not yet been done for head and neck squamous cell carcinoma (HNSCC).